ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies
Mar 14
2024
American Society of Hematology. (2024).
ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-secondary-malignancies-associated-with-car-t-cell-therapies.
American Society of Hematology.
"ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-secondary-malignancies-associated-with-car-t-cell-therapies
(label-accessed March 16, 2025).
"American Society of Hematology."
ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies, 16 Mar. 2025 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-secondary-malignancies-associated-with-car-t-cell-therapies.
